The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 165-175

  Breitenstein, Barbara ^a,b   Scheuer, Sandra ^b   Pfister, Hildegard ^b   Uhr, Manfred ^b   Lucae, Susanne ^b   Holsboer, Florian ^a,b   Ising, Marcus ^b   Brückl, Tanja M ^b  

^a HolsboerMaschmeyer NeuroChemie   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

ABCB1; antidepressant treatment outcome; major depression; P glycoprotein; pharmacogenetic testing

Indexed keywords

ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN 1; ABC TRANSPORTER A1; AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DOXEPIN; ESCITALOPRAM; FLUOXETINE; GUANINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; SERTRALINE; THYMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ABCB1 GENE; ADULT; ALLELE; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL DECISION MAKING; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG MECHANISM; FEMALE; GENE; GENOTYPE; HAMILTON SCALE; HOMOZYGOTE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CHI SQUARE DISTRIBUTION; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; BIPOLAR DISORDER; GENETIC SCREENING; HOSPITAL DISCHARGE; HOSPITAL PATIENT; LENGTH OF STAY; MAJOR DEPRESSION; OUTCOME ASSESSMENT; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ATP BINDING CASSETTE TRANSPORTER 1; CHI-SQUARE DISTRIBUTION; DEPRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84901707207     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000436     Document Type: Article

References (44)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006; 163(11): 1905-1917. (Pubitemid 44807782)
2. Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012; 13(4): 441-464.
3. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009; 124(1): 57-73.
4. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003; 54(8): 840-846. (Pubitemid 37205136)
5. Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C.T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007; 29(2): 185-189. (Pubitemid 46716184)
6. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008; 57(2): 203-209.
7. Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008; 30: 474-482.
8. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(2): 398-404. (Pubitemid 351178955)
9. Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Res. 2008; 58(5-6): 344-347.
10. Sarginson JE, Lazzeroni LC, Ryan HS, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics. 2010; 20(8): 467-475.
11. Lin K-M, Chiu Y-F, Tsai I-J, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics. 2010; 21(4): 163-170.
12. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011; 12(3): 365-377.
13. De Klerk OL, Nolte IM, Bet PM, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J.2012; 1-5.
14. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. In press. DOI: 10.1038/tp.2012.115.
15. Laika B, Leucht S, Steimer W. ABCB1 (P-glycoprotein/ MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem. 2006; 52(5): 893-895. (Pubitemid 43673271)
16. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. Baune B, ed. PLoS One. 2008; 3(4): e1872.
17. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: Therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1439-1444.
18. Dong C, Wong M-L, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry. 2009; 14(12): 1105-1118.
19. Menu P, Gressier F, Verstuyft C, et al. Antidepressants and ABCB1 gene C3435T functional polymorphism: A naturalistic study. Neuropsychobiology. 2010; 62(3): 193-197.
20. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry. 2010; 67(11): 1110-1113.
21. Uher R, Perroud N, Ng MYM, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010; 167(5): 555-564.
22. Holsboer F. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci. 2008; 9(8): 638-646.
23. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009; 43(3): 215-229.
24. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009; 66(9): 966-975.
25. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 2005; 76(5): 887-893. (Pubitemid 40563110)
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2): 263-265. (Pubitemid 40202029)
27. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000; 22(4): 380-387. (Pubitemid 30105766)
28. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41(1-2): 179-188. (Pubitemid 44708204)
29. Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003; 37(3): 179-185. (Pubitemid 36313270)
30. Wang J-S, Zhu H-J, Gibson B-B, et al. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008; 31(2): 231-234. (Pubitemid 351198395)
31. Chiu H-W, Li T-C. Rapid weight gain during mirtazapine treatment. J Neuropsychiatry Clin Neurosci. 2011; 23: E7.
32. Roose SP. Tolerability and patient compliance. J Clin Psychiatry. 1999; 60(suppl 17): 14-17; discussion 46-48. (Pubitemid 29386034)
33. Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. Encephale. 1999; 25(5): 470-476.
34. Ju rgens G, Jacobsen CB, Rasmussen HB, et al. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice. Acta Psychiatr Scand. 2012; 125(3): 228-237.
35. O'Brien FE, Clarke G, Fitzgerald P, et al. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol. 2012; 166(4): 1333-1343.
36. Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 2007; 32(4): 757-764. (Pubitemid 46426181)
37. Feng B, Mills JB, Davidson RE, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008; 36(2): 268-275. (Pubitemid 351185738)
38. Colabufo NA, Berardi F, Cantore M, et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J Med Chem. 2010; 53(5): 1883-1897.
39. Mrazek DA, Biernacka JM, O'Kane DJ, et al. CYP2C19 variation and citalopram response. Pharmacogenet Genomics. 2011; 21(1): 1-9.
40. Horstmann S, Lucae S, Menke A, et al. Association of GRIK4 and HTR2A genes with antidepressant treatment in the MARS cohort of depressed inpatients. Eur Neuropsychopharmacol. 2008; 18(suppl 4): 214-215.
41. Lucae S, Ising M, Horstmann S, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol. 2010; 20(1): 65-68.
42. Porcelli S, Fabbri C, Serretti A. Meta-Analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012; 22(4): 239-258.
43. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007; 164(8): 1181-1188. (Pubitemid 47292406)
44. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004; 36(12): 1319-1325. (Pubitemid 39577942)